-
-
Tackle the Crackle©
Pulmonary fibrosis (PF) is often difficult to diagnose, with patients waiting an average of two years for a confirmed diagnosis. Early symptoms can be subtle and mistaken for other lung conditions. These Tackle the Crackle© resources support early detection, help you prepare for conversations with your healthcare team, and connect you with PF specialists and…
-
The Connection Between Connective Tissue Diseases and Pulmonary Fibrosis – Dr. Pope
Did you know connective tissue diseases like rheumatoid arthritis, scleroderma, lupus, sjögren’s and others can increase your risk of pulmonary fibrosis? In this CPFF educational video, Dr. Janet Pope breaks down the crucial connection, explaining in an easy-to-understand way, the early signs, treatment options, and steps you can take. Make sure taking care of your…
-
COVID-19 & Pulmonary Fibrosis: Know the Signs of PF
Farrell Eckman shares her COVID-related PF journey, and respirologist Dr. Daniel Marinescu contributes his expertise on the relationship between PF and COVID-19.
-
Pulmonary Fibrosis Symptoms: Listen for the Signs
Respirologists Dr. Deborah Assayag, Dr. Amanda Grant-Orser, and Dr. Charlene Fell educate viewers on how to listen for the signs of early PF symptoms and when to ask your doctor to tackle the tell-tale lung crackles.
-
Find a Family Doctor or Walk-in Clinic – Provincial Resources
There is no doubt that your family doctor (or nurse practitioner) is the gateway to accessing the health care system in your province or territory. Unfortunately, millions of Canadians do not have a primary care physician. CPFF has gathered some links that may help you to find a family physician, or a walk-in clinic, in…
-
FIBRONEER-IPF: A Phase 3 Clinical Trial – Dr. Donald Zoz
FIBRONEER-IPF: A Phase 3 Clinical Trial – Dr. Donald Zoz This presentation, led by Dr. Donald Zoz MD, senior clinical program leader at Boehringer Ingelheim, provides some insight into FIBRONEER-IPF, a Phase 3 Clinical Trial. The goal of FIBRONEER-IPF Phase 3 Clinical Trial is to evaluate the efficacy, safety, and tolerability of the compound BI…
-
April 2023 PF News
What is Idiopathic Pulmonary Fibrosis? IPF Part 1 Update on Interstitial Lung Disease 2020 | American Journal of Respiratory and Critical Care Medicine
-
March 2023 PF News
Canadians with a rare disease are at a disadvantage when it comes to healthcare Yale researchers discover new approach to reversing lung scarring Government of Canada improves access to affordable and effective drugs for rare diseases New clinician toolkit aims to close the gaps in diagnosis of interstitial lung diseases







